RBC Capital Keeps a Hold Rating on Theratechnologies (THTX)

In a report issued on January 7, Brian Abrahams from RBC Capital maintained a Hold rating on Theratechnologies (THTXResearch Report), with a price target of $2.00. The company’s shares closed last Wednesday at $2.58.

According to TipRanks.com, Abrahams is a 4-star analyst with an average return of 8.6% and a 47.9% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals, Intra-Cellular Therapies, and Karyopharm Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Theratechnologies with a $3.58 average price target.

See today’s analyst top recommended stocks >>

Based on Theratechnologies’ latest earnings release for the quarter ending August 31, the company reported a quarterly revenue of $14.05 million and GAAP net loss of $6.77 million. In comparison, last year the company earned revenue of $16.11 million and had a GAAP net loss of $1.64 million.

Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of THTX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Theratechnologies, Inc. is a pharmaceutical company. It engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The firm offers its product under the brand name of EGRIFTA, which approved therapy for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies was founded on October 19, 1993 and is headquartered in Montreal, Canada.